These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 22335410

  • 21. Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma.
    Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P, Lang-Lazdunski L.
    J Thorac Oncol; 2010 Mar; 5(3):385-8. PubMed ID: 20087231
    [Abstract] [Full Text] [Related]

  • 22. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
    Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols Iii FC, Aubry MC, Jett JR.
    Clin Lung Cancer; 2009 Jul; 10(4):244-8. PubMed ID: 19632941
    [Abstract] [Full Text] [Related]

  • 23. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters.
    Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, Byrne MJ.
    Clin Cancer Res; 2010 Apr 15; 16(8):2409-17. PubMed ID: 20371686
    [Abstract] [Full Text] [Related]

  • 24. Integrated FDG PET-CT imaging improves staging in malignant pleural mesothelioma.
    Krüger S, Pauls S, Mottaghy FM, Buck AK, Schelzig H, Hombach V, Reske SN.
    Nuklearmedizin; 2007 Apr 15; 46(6):239-43. PubMed ID: 18084678
    [Abstract] [Full Text] [Related]

  • 25. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P, Buchbender C, Köhler J, Nensa F, Gauler T, Gomez B, Reis H, Stamatis G, Kühl H, Hartung V, Heusner TA.
    J Nucl Med; 2014 Mar 15; 55(3):373-8. PubMed ID: 24504054
    [Abstract] [Full Text] [Related]

  • 26. Positron emission tomography predicts survival in malignant pleural mesothelioma.
    Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM, Rusch VW.
    J Thorac Cardiovasc Surg; 2006 Oct 15; 132(4):763-8. PubMed ID: 17000285
    [Abstract] [Full Text] [Related]

  • 27. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival.
    Gerbaudo VH, Mamede M, Trotman-Dickenson B, Hatabu H, Sugarbaker DJ.
    Eur J Nucl Med Mol Imaging; 2011 May 15; 38(5):810-21. PubMed ID: 21210110
    [Abstract] [Full Text] [Related]

  • 28. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA.
    Eur J Radiol; 2012 Jan 15; 81(1):e19-25. PubMed ID: 21129871
    [Abstract] [Full Text] [Related]

  • 29. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y, Takuwa T, Miyata Y, Fukuoka K, Hasegawa S, Nakano T, Okada M.
    Ann Oncol; 2013 Apr 15; 24(4):1005-10. PubMed ID: 23136224
    [Abstract] [Full Text] [Related]

  • 30. 18F-fluorodeoxyglucose positron emission tomography in malignant pleural mesothelioma: diagnostic and prognostic performance and its correlation to pathological results.
    Lococo F, Rena O, Torricelli F, Filice A, Rapicetta C, Boldorini R, Paci M, Versari A.
    Interact Cardiovasc Thorac Surg; 2020 Apr 01; 30(4):593-596. PubMed ID: 32003806
    [Abstract] [Full Text] [Related]

  • 31. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
    Schrepfer T, Haerle SK, Strobel K, Schaefer N, Hälg RA, Huber GF.
    Laryngoscope; 2010 May 01; 120(5):937-44. PubMed ID: 20422687
    [Abstract] [Full Text] [Related]

  • 32. Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
    Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.
    Cancer Med; 2017 Oct 01; 6(10):2287-2296. PubMed ID: 28941158
    [Abstract] [Full Text] [Related]

  • 33. Predicting pleural invasion using HRCT and 18F-FDG PET/CT in lung adenocarcinoma with pleural contact.
    Tanaka T, Shinya T, Sato S, Mitsuhashi T, Ichimura K, Soh J, Toyooka S, Kaji M, Miyoshi S, Kanazawa S.
    Ann Nucl Med; 2015 Nov 01; 29(9):757-65. PubMed ID: 26142739
    [Abstract] [Full Text] [Related]

  • 34. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma.
    Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, Endo M, Kondo H, Nakajima T, Yamamoto N.
    Eur J Cancer; 2012 May 01; 48(8):1244-54. PubMed ID: 22330319
    [Abstract] [Full Text] [Related]

  • 35. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
    Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ.
    J Nucl Med; 2007 Sep 01; 48(9):1449-58. PubMed ID: 17704250
    [Abstract] [Full Text] [Related]

  • 36. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA, Hoang JK, Roach MC, Chino J, Yoo DS, Turkington TG, Brizel DM.
    Int J Radiat Oncol Biol Phys; 2012 Feb 01; 82(2):548-53. PubMed ID: 21277108
    [Abstract] [Full Text] [Related]

  • 37. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 38. Role of 18F-FDG PET for evaluating malignant pleural mesothelioma.
    Nanni C, Castellucci P, Farsad M, Pinto C, Moretti A, Pettinato C, Marengo M, Boschi S, Franchi R, Martoni A, Monetti N, Fanti S.
    Cancer Biother Radiopharm; 2004 Apr 20; 19(2):149-54. PubMed ID: 15186594
    [Abstract] [Full Text] [Related]

  • 39. Prognostic value of FDG PET imaging in malignant pleural mesothelioma.
    Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A.
    J Nucl Med; 1999 Aug 20; 40(8):1241-5. PubMed ID: 10450672
    [Abstract] [Full Text] [Related]

  • 40. High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: supportive evidence to reclassify pleomorphic as nonepithelioid histology.
    Kadota K, Kachala SS, Nitadori J, Suzuki K, Dunphy MP, Sima CS, Travis WD, Rusch VW, Adusumilli PS.
    J Thorac Oncol; 2012 Jul 20; 7(7):1192-7. PubMed ID: 22617244
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.